Chemokine Receptors as Biomarkers in Head and Neck Squamous Cell Carcinoma

Abstract

Head and neck squamous cell carcinoma (HNSCC) is reported to be the 6th most common solid tumor diagnosed in the world [1]. Around 95% head and neck cancers are squamous cell carcinomas originating in the upper aerodigestive epithelial cells [2]. Despite continuous research efforts and progresses in diagnostic and therapeutic strategies, the mortality rates have not significantly changed over the past several decades [3]. Moreover, the five-year survival rate of HNSCC after diagnosis is considerably lower than that of other cancers, such as cervix, colorectal and breast cancer [4,5]. The reason for the limited five-year survival rate of HNSCC could be advanced disease stages, failure in early diagnosis and low efficiency of therapeutic strategies [6,7]. The death of HNSCC is mainly caused by invasion along with regional and/or distant metastatic spreading of tumor cells from primary tumor lesions [8]. Therefore, the key point of the treatment of head and neck cancers is early diagnosis. So far, numerous genes related to tumorigenesis and tumor progression have been identified and characterized. Some of them, such as c-myc, Ras, P53, P63, cyclin D1 etc., are expressed abnormally in head and neck cancers [3,9-11]. Moreover, other aberrantly expressed proteins have also been found in head and neck carcinoma lesions, including PTEN [12,13], p27 [3,14], p21 [15] as well as annexins [16], which play significantly roles in the progression, malignancy and prognosis in head and neck carcinoma. These discoveries are helpful in early diagnosis of HNSCC. Meanwhile, the importance of chemokines and their cognate receptors in head and neck cancers is being revealed by increasing amount of studies. Recently, the expression of CXC chemokine receptor 2 (CXCR2) was reported substantially higher than that in paraneoplastic tissue in laryngeal squamous cell carcinoma [17]. The authors also found that the elevated expression was significantly related with lymph node metastasis, histological grade, and 5-year survival [17]. They concluded that CXCR2 expression could be considered as a potent prognostic marker for laryngeal squamous cell carcinoma patients [17]. Several studies have also documented the significance of CXCR4 in HNSCC tumor progression and organ-specific metastasis [18,19]. Wang et al investigated the expression of CXCR4 in nasopharyngeal carcinoma tissues, and they found that CXCR4 expression was elevated in tumor tissues and the increased expression was correlated with metastatic rates in patients as well as poor overall survival [20]. This finding was consistent with another study which reported that CXCR4 mRNA was significantly higher in HNSCC tissues than in paraneoplastic tissues and its expression were associated with lymph node metastasis and distant metastasis [21]. These findings clearly demonstrate that CXCR4 could also be used to predict prognosis and metastasis in HNSCC patients.